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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To determine the diagnostic accuracy of ultrasonography for detecting the presence or absence of cirrhosis in people with alcoholic
liver disease compared with liver biopsy as reference standard.
To determine the diagnostic accuracy of any of the ultrasonography tests, B-mode or Echo-colour Doppler ultrasonography, used
singly or combined, or plus ultrasonography signs, or a combination of these, for detecting hepatic cirrhosis in people with alcoholic
liver disease compared with liver biopsy as a reference standard, irrespective of sequence. If results differ, we will attempt to explore
heterogeneity analysing:
• liver biopsy as the reference standard:
◦ different grade of inflammation (amount of ongoing inflammation and necrosis) according to the liver biopsy (below two
grades compared to two or greater grades of activity);
◦ different lengths of liver biopsy sample (shorter than 15 mm compared to 15 mm or longer) or number of portal tracts
(fewer than six compared to six or more), as reported in the studies;
◦ percutaneous liver biopsy versus transvenous (transjugular) liver biopsy versus laparoscopic liver biopsy;
• different technical characteristics of the ultrasonography equipment (e.g., different transducers, different wave lengths);
• different skills of the operator as stated by the authors;
• complete abstinent (teetotallers) or non-abstinent study participants (as defined in the included studies).
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• different grade of inflammation (amount of ongoing inflammation and necrosis) according to the liver biopsy (below two grades
compared to two or greater grades of activity);
• different lengths of liver biopsy sample (shorter than 15 mm compared to 15 mm or longer) or number of portal tracts (fewer
than six compared to six or more), as reported in the studies;
• percutaneous liver biopsy versus transvenous (transjugular) liver biopsy versus laparoscopic liver biopsy;
In addition, we will attempt to identify the most accurate ultrasonographic tests and indices for diagnosis of cirrhosis in people with
alcoholic liver disease.
B A C K G R O U N D
Alcohol consumption is a worldwide problem. Every year approx-
imately 2.5 million people die of it; 320,000 of them are young
people between 15 and 29 years of age. Based on estimates for
2004, alcohol was responsible for almost 4% of all deaths in the
world (WHO 2010).
Heavy alcohol consumption causes alcoholic liver disease and is
a causal factor of many types of liver injuries and concomitant
diseases. It is a true systemic disease that may damage the digestive
tract, the nervous system, the heart and vascular system, the bone
and skeletalmuscle system, and the endocrine and immune system,
and can lead to cancer (WHO 2010; Rocco 2014).
Liver damage in turn, can present as multiple alcoholic liver dis-
eases, including fatty liver, steatohepatitis, fibrosis, alcoholic cir-
rhosis, and hepatocellular carcinoma, with presence or absence
of hepatitis B or hepatitis C virus infection (Brunt 1974; Bruha
2012; Testino 2014). There are three scarring types (fibrosis) that
are most commonly found in alcoholic liver disease: centrilobular
scarring, pericellular fibrosis, and periportal fibrosis. When liver
fibrosis progresses, alcoholic cirrhosis occurs. Hepatocellular car-
cinoma occurs in 5% to 15% of people with alcoholic cirrhosis,
but people in whom hepatocellular carcinoma has developed are
often co-infected with hepatitis B or C virus (MacSween 1986;
Jaurigue 2014).
Abstinence from alcohol may help people with alcoholic disease
in improving their prognosis of survival at any stage of their dis-
ease; however, the more advanced the stage, the higher the risk of
complications, co-morbidities, and mortality, and lesser the effect
of abstinence (Borowsky 1981). Being abstinent one month after
diagnosis of early cirrhosis will improve the chance of a seven-year
life expectancy by 1.6 times (Verrill 2009). Liver transplantation
is the only radical method that may change the prognosis of a per-
son with alcoholic liver disease; however, besides the difficulties
of finding a suitable liver transplant organ, there are many other
factors that may influence a person’s survival (Iruzubieta 2013;
Singal 2013).
Cochrane systematic reviews of randomised clinical trials of phar-
macological interventions used for reducing alcohol consumption
such as acamprosate, benzodiazepines, naltrexone, gamma-hy-
droxybutyrate, baclofen (derivative of gamma-aminobutyric acid),
and anticonvulsants versus placebo or another drug in alcohol-de-
pendent people have studied the benefits and harms of these inter-
ventions for alcohol reduction or withdrawal (Amato 2010; Leone
2010; Minozzi 2010; Rösner 2010a; Rösner 2010b; Liu 2013;
Pani 2014). However, the conclusions, despite showing some po-
tential tendency of alcohol reduction or promotion of abstinence,
lack the desired robustness of evidence as the performed ran-
domised clinical trials for alcohol withdrawal with the suggested
drug interventions either fail in quality, are of insufficient sample
size, are too heterogeneous, or lack sufficient evidence for benefits.
Without diminishing nutritional and supportive management of
people with alcoholic liver disease, complete abstinence from al-
cohol seems still to be the only recommended form of hepatopro-
tection.
Ultrasound is an inexpensive method used for years in clinical
practice to diagnose alcoholic cirrhosis (Rockey 2009; O’Shea
2010).Ultrasoundparameters for assessing cirrhosis in peoplewith
alcoholic liver disease encompass amongothers liver size, bluntness
of the liver edge, coarseness of the liver parenchyma, nodularity
of the liver surface, size of the lymph nodes around the hepatic
artery, irregularity and narrowness of the inferior vena cava, portal
vein velocity, and spleen size (Nishiura 2005).
In a series of 1604 people with alcoholic liver disease diagnosed
on liver biopsy or clinically confirmed diagnosis, 608 (38%) peo-
ple had developed alcoholic cirrhosis (Naveau 1997). Diagnosis
of cirrhosis by ultrasound, especially in people who were asymp-
tomatic, may have its advantages for the prognosis, motivation,
and treatment of these people to decrease their alcohol consump-
tion or become abstinent (O’Shea 2010).
Timely diagnosis of alcoholic cirrhosis in people with alcoholic
liver disease is the cornerstone for evaluation of prognosis or choos-
ing treatment strategies in these people.
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Target condition being diagnosed
Cirrhosis in people with alcoholic liver disease
All people with alcoholic liver disease are at risk of developing liver
fibrosis and cirrhosis. This risk is considered higher in people who
are binge drinkers, people with increased serum alanine amino-
transferase and aspartate aminotransferase levels, or in people with
severe alcohol hepatitis on liver biopsy (Bouchier 1992). Cirrhosis
may have symptoms and signs of liver disease, and cirrhosis may
vary from one person to another. In general, people with alco-
holic liver disease see a doctor when symptoms and signs from the
complications of cirrhosis have already developed (O’Shea 2010).
Physicians should attempt tomotivate people to stop drinking. In-
direct evidence of alcohol abuse can be collected through question-
naires about drinking habits, through information received from
family members, and through running laboratory tests (O’Shea
2010).
Hepatic fibrosis may develop as a result of weekly alcohol con-
sumption of seven to 13 beverages for women (one beverage =
12 g of alcohol) and 14 to 27 beverages for men in the course of
five or more years (Savolainen 1993; Becker 1996). The risk ratio
of progression of fibrosis to cirrhosis increases significantly with a
daily consumption of 20 to 40 g of ethanol in women and more
than 80 g of ethanol in men (Sherlock 1997; O’Shea 2010).
The liver is themain site of alcoholmetabolism acting through two
hepatic enzymes, alcohol dehydrogenase and cytochrome P-450
(CYP) 2E1. Increased alcohol intake disrupts the metabolic liver
function, and, as a result, alcoholic liver disease develops (Stewart
2001).
METAVIR is the most widely used scoring system for interpre-
tation of liver biopsy results based on the stage of fibrosis where
F0 indicates no fibrosis, F1 indicates portal fibrous expansion, F2
indicates thin fibrous septa emanating from portal triads, F3 in-
dicates fibrous septa bridging portal triads and central veins, and
F4 indicates cirrhosis (Table 1).
Michalak 2003 validated the reproducibility of the METAVIR
score, using a slightly modifiedMETAVIR score, that is, the portal
tract/septal fibrosis score, to investigate the amount of fibrosis and
study the influence of centrilobular fibrosis and portal tract/septal
fibrosis in alcoholic chronic liver disease. The amount of portal
tract/septal fibrosis in people with alcoholic chronic disease was
greater than the amount of centrilobular fibrosis in the control
group of people with viral chronic hepatitis disease, which sug-
gested that portal tract/septal fibrosis was more frequent in alco-
holic chronic liver disease than in viral chronic hepatitis. However,
centrilobular fibrosis forms with the advance of fibrosis in cirrho-
sis. The prognostic value of the METAVIR fibrosis score in alco-
holic liver disease still needs to be established (Michalak 2003).
In Table 1, we have included other widely used systems for classi-
fication of fibrosis in people with alcoholic liver disease (Knodell
1981; Desmet 1994; Ishak 1995; Brunt 1999; Kleiner 2005).
However, as the focus of our review is on alcoholic cirrhosis alone,
for discrepancies in classification of cirrhosis, we refer the readers
to the last two rows of the table (shaded).
Index test(s)
Ultrasonography is used in clinical practice for diagnosis of cirrho-
sis in people with alcoholic liver disease as it allows investigation of
the hepatic tissue through the generation of ultrasonic waves. B-
mode and Echo-colour Doppler ultrasonography seem to be the
most often used methods for diagnosis of cirrhosis.
Ultrasonic patterns obtained at ultrasonography investigation in
B-mode are usually classified as positive or negative considering
signs, for example parenchymal (liver surface, volume, edge, and
texture), extrahepatic (spleen volume, presence of ascites), and
vascular (diameter of portal and spleen veins), used in different
combinations and defined as indices. Hepatic fibrosis produces
abnormal echo patterns on ultrasound scanning. Much higher
attenuation is observed at examination of the liver of people with
steatosis compared to the liver of people with hepatic fibrosis (
Bamber 1979; Saverymuttu 1986).
Vascular (Doppler) indices, such as Doppler perfusion index, hep-
atic transit time, portal vein congestive index, and various ratios
analysing different blood vessels, are used indirectly for detection
of portal hypertension and cirrhosis ((Ersoz 1999; Hizli 2010;
Ivashkin 2011a).
The sensitivity and specificity of ultrasonography investigation for
diagnosis of cirrhosis in people with alcoholic liver disease, despite
their wide use, have not been established in systematic reviews yet.
Clinical pathway
Figure 1 presents the clinical pathway in the diagnosis of alcoholic
liver cirrhosis.
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Figure 1. Clinical pathway in the diagnosis of alcoholic liver disease.
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Alternative test(s)
Differentmethods to assess liver fibrosis have been developed since
1990. Most of them are aimed at quantifying the elasticity or
viscoelasticity of the liver tissue. There are two common elements
in every elasticity imaging method: a force or stress is applied on
the liver tissue and the obtained mechanical response is measured.
Acoustic radiation force impulse (ARFI) (ACUSON S2000;
Siemens Ltd.) is a non-invasive imaging technique that can detect
and quantify hepatic fibrosis. The ARFI technology is also called
liver ultrasound elastography (Iyo 2009). ARFI imaging is faster
than conventional methods as ARFI uses higher frequencies that
are comparable to those used in colour Doppler imaging. The im-
ages have greater contrast and the boundary of the focal lesions
are better defined compared with conventional ultrasonography
imagining techniques (Iyo 2009).
Supersonic shear imaging investigates tissue elasticity to detect
hepatic fibrosis and steatosis. It is based on velocity estimation of
a shear wave, generated by a radiation force (Bercoff 2004).
Magnetic resonance elastography combines magnetic resonance
imaging with sound waves to create a visual map (elastogram)
showing the stiffness of the liver tissue. It is used primarily to detect
hardening of the liver caused by different types of liver diseases,
including those of alcoholic aetiology (Yin 2007).
Transient elastography is another non-invasive method for assess-
ment of hepatic fibrosis (Gómez-Domínguez 2006; Pavlov 2015),
whichmeasures hepatic fibrosis through the stiffness of the hepatic
parenchyma. Transient elastography measures the speed of prop-
agation of the elastic wave through the hepatic parenchyma: the
stiffer the tissue, the faster the shear wave propagates the obtained
hepatic stiffness, expressed as a median value in kiloPascals (kPa).
Other alternative non-invasive tests (apart from venepuncture)
are laboratory tests such as aspartate aminotransferase to ala-
nine aminotransferase ratio, platelet count, prothrombin index,
hyaluronic acid, and enhanced liver fibrosis score (Crespo 2012;
Liu 2012). All of these tests are used as surrogate markers for stag-
ing of hepatic fibrosis. In addition, different combinations of bio-
chemical tests such as FibroTest® and Fibrometre® are used for
diagnosis and staging of hepatic fibrosis in people with alcoholic
liver disease (Morra 2007; Poynard 2007; Poynard 2008; Angulo
2009).
Rationale
Liver biopsy has so far been considered the standard method for
detection of hepatic fibrosis and its staging, using different semi-
quantitativemorphological scores on liver tissue sampleswith a size
of nomore than1 to2 cm3 (Table 1).One advantage of liver biopsy
is that it may give diagnostic information for concurrent liver
diseases (Poulsen 1979; Ismail 2011).However, there are a number
of disadvantages with liver biopsy. It is invasive, and it may have
potential risks to the person such as punctures of abdominal organs
and haemorrhage. Liver biopsy can be painful, time-consuming,
and stressful for the person (Grant 1999; O’Shea 2010; Ivashkin
2011b). The risk of haemorrhage and death after a percutaneous
liver biopsy is especially higher in people with a platelet count of
60,000 per mm3 or less (Seeff 2010). Transjugular liver biopsy
seems a safer alternative for people with low platelet counts or
clotting abnormalities. The small size of the tissue samples, either
obtained transcutaneously or via the transjugular route, may also
lead to sampling errors.
The technical possibilities of the ultrasonography equipment and
the individual experience of the investigator performing the ultra-
sonography are the main factors influencing the precision of the
ultrasound examination. Consensus on using ultrasonography as
a non-invasive method for diagnosis of cirrhosis in people with
alcoholic liver disease seems not to have been established, despite
being widely used instead of, or together with, other non-inva-
sive techniques (Shiha 2009). When a person presents with clini-
cal symptoms (e.g., ascites, encephalopathy, oesophageal bleeding)
of cirrhosis, neither liver biopsy nor ultrasonography are needed.
However, in case of insufficient or unclear expression of clinical
signs, a wait-and-see approach, ultrasonography, or other alterna-
tive non-invasive tests may be considered before arranging a liver
biopsy investigation (Figure 1). As cirrhosis is a main prognostic
variable with impact on survival of people with alcoholic liver dis-
ease, it is important to detect cirrhosis, assess the risk of complica-
tions, and encourage abstinence of drinking alcohol (Leong 2012;
Singal 2013; Testino 2014).
This review aims to meta-analyse data from studies on the diagno-
sis of cirrhosis in people with alcoholic liver disease and to assess
the diagnostic accuracy of ultrasonography in detecting the pres-
ence of cirrhosis compared with liver biopsy as reference standard,
following The Cochrane Collaboration methodology (SRDTA
Handbook).
We did not identify any meta-analysis or systematic review on the
use of ultrasonography for defining the presence of cirrhosis in
people with alcoholic liver disease. A Cochrane systematic diag-
nostic test accuracy review on ultrasonography in detecting cir-
rhosis in people with alcoholic liver disease compared with liver
biopsy does not exist either. Therefore, we have planned to con-
duct this review.
O B J E C T I V E S
To determine the diagnostic accuracy of ultrasonography for de-
tecting the presence or absence of cirrhosis in people with alcoholic
liver disease compared with liver biopsy as reference standard.
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Secondary objectives
To determine the diagnostic accuracy of any of the ultrasonogra-
phy tests, B-mode or Echo-colour Doppler ultrasonography, used
singly or combined, or plus ultrasonography signs, or a combina-
tion of these, for detecting hepatic cirrhosis in people with alco-
holic liver disease compared with liver biopsy as a reference stan-
dard, irrespective of sequence. If results differ, we will attempt to
explore heterogeneity analysing:
• liver biopsy as the reference standard:
◦ different grade of inflammation (amount of ongoing
inflammation and necrosis) according to the liver biopsy (below
two grades compared to two or greater grades of activity);
◦ different lengths of liver biopsy sample (shorter than
15 mm compared to 15 mm or longer) or number of portal
tracts (fewer than six compared to six or more), as reported in the
studies;
◦ percutaneous liver biopsy versus transvenous
(transjugular) liver biopsy versus laparoscopic liver biopsy;
• different technical characteristics of the ultrasonography
equipment (e.g., different transducers, different wave lengths);
• different skills of the operator as stated by the authors;
• complete abstinent (teetotallers) or non-abstinent study
participants (as defined in the included studies).
In addition, we will attempt to identify the most accurate ultra-
sonographic tests and indices for diagnosis of cirrhosis in people
with alcoholic liver disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Diagnostic cohort study designs and diagnostic case-control study
designs that had assessed cirrhosis in participants with alcoholic
liver disease through ultrasonography and liver biopsy, irrespective
of language or publication status, or whether data were collected
prospectively or retrospectively. We may also include randomised
clinical trials or controlled clinical studies if they fulfil the inclusion
criteria of our review protocol.
We will include studies published as full paper articles, in the form
of abstracts published in conference proceedings or presented as
posters if the abstracts are identified with the searches.
We will also consider studies for inclusion if they had included
participants with different aetiologies of liver disease.
Participants
Participants of any sex and ethnic origin, over 16 years old, and
diagnosed with alcoholic liver disease, following study authors’
statements. The participants could have been hospitalised or man-
aged as outpatients.
The diagnosis of alcoholic liver disease in the study participants
should have been established based on registered history of ex-
cessive alcohol intake of sufficient duration and quantity together
with clinical evidence of liver disease expressed with physical signs
at examination and followed by laboratory evidence of liver dis-
ease. To ascertain the diagnosis of alcoholic liver disease and study
the presence or absence of cirrhosis, both ultrasonography and
liver biopsy should have been performed, irrespective of the se-
quence.
We will also include participants if suspected of having non-alco-
holic fatty liver disease, in addition to diagnosed alcoholic liver
disease.
We will not consider for inclusion participants diagnosed with
alcoholic liver disease and having a concomitant liver disease such
as chronic hepatitis C virus infection, chronic hepatitis B virus
infection, autoimmune liver disease, or human immunodeficiency
virus (HIV) infection. We will extract data on study participants
with alcoholic liver disease alone whenever such data are available
in the study report or whenever we can obtain the data required for
the review through personal communication with study authors.
In the latter case, we may disregard some of the data presented in
the publication and use the data provided by the study authors
through personal communication.
Index tests
Ultrasonography in any mode.
As we expect that study authors would have used different mea-
surements, signs, and combinations of signs for assessment of cir-
rhosis by ultrasonography with different techniques and mode, we
cannot specify these here. However, we will consider parenchy-
mal, vascular, and extrahepatic ultrasonographic signs as different
index tests.
Target conditions
There are five stages of liver fibrosis by METAVIR (Table 1):
• F0 = no fibrosis;
• F1 = mild fibrosis;
• F2 = significant fibrosis;
• F3 = severe fibrosis;
• F4 = cirrhosis.
The target condition is the presence of cirrhosis in people with
alcoholic liver disease, defined using the METAVIR score.
Thus, wewill dichotomise the fibrosis estimated by theMETAVIR
score as follows: we will consider people with a METAVIR score
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of F4 as ’diseased’ and people with a METAVIR score of F0 plus
F1 plus F2 plus F3 as ’non-diseased’.
Reference standards
Liver biopsy is the reference standard that is obtained by percu-
taneous needle techniques with needles 1.4 to 1.6 mm (16 to 18
gauge) in diameter, transjugular method, or surgical specimens
(Kuntz 2008; Ivashkin 2011b).
Liver biopsy is the only existing reference standard for diagnosing
hepatic cirrhosis in people with alcoholic liver disease. Specimens
of liver tissue with a length of at least 15 mm and at least six portal
tracts are among the factors that canprovide reliablemorphological
diagnosis of cirrhosis (Bedossa 2003; Colloredo 2003; Rockey
2009).
If liver biopsy samples are reported with any of the semi-quan-
titative scores, that is, METAVIR (Michalak 2003), Knodell
(Franciscus 2007), Ishak (Franciscus 2007), Kleiner (Kleiner
2005), Scheuer (Regev 2002), Brunt (Brunt 1999), or Batts-Lud-
wig (Haque 2010), we will use a conversion grid for hepatic fibro-
sis staging adapted after Goodman 2007 to only unify results for
hepatic cirrhosis on liver biopsy (Table 1). METAVIR has already
been validated for staging alcoholic cirrhosis (Michalak 2003).
Search methods for identification of studies
We will combine electronic searches with reading references of
identified studies of possible interest.
Electronic searches
We will search The Cochrane Hepato-Biliary Group Controlled
Trials Register, The Cochrane Hepato-Biliary Group Diagnos-
tic Test Accuracy Studies Register (hbg.cochrane.org/specialised-
register), The Cochrane Library (Wiley), MEDLINE (PubMed),
EMBASE (Ovid SP), and the Science Citation Index Expanded
(de Vet 2010). We will specify the time period of the listed
databases that we search at the review stage (Appendix 1). We will
apply no language limitations.
Searching other resources
We will also screen references of the retrieved studies to identify
other potentially relevant studies for inclusion in our review. We
will consider extracting data from studies presented in an abstract
or poster form, or from grey literature only if data for our review
can be found.
Appendix 1 shows the search strategies for the different databases
with the time spans for the searches.
Data collection and analysis
We will follow the guidelines provided in the Cochrane Diagnostic
Reviewer’s Handbook (still in draft).
Selection of studies
Three review authors (CP,MP, andEL)will independently identify
studies for possible inclusion in the review. While reading titles or
abstracts or both of the identified studies, wewill exclude references
with a study design not fulfilling the inclusion criteria of our review
protocol. We will retrieve the full text of the remaining references.
During this second selection stage, wewill group togethermultiple
publications of one study fulfilling the inclusion criteria, and then
we will screen these publications for complimentary data or we
will check them for discrepancies. If in doubt, CP, GC, and DN
will write e-mails to study authors.
The studies that we will include shall evaluate ultrasound in the
diagnosis of hepatic cirrhosis using only liver biopsy as the refer-
ence standard.
The maximum time interval of investigation with liver biopsy
and ultrasonography should not exceed six months. In addition,
ultrasonography could have been performed before or after liver
biopsy.
Data extraction and management
Three review authors (CP,GC, andMP)will independently extract
data following the protocol. Two of the other review authors (DN
andMT) will check the extraction of all study data. A sixth review
author (CG) will be an arbitrator in case of disagreements between
review authors.
The data needed for the conductance of this systematic review will
be study origin, year and language of publication, study design,
participants’ epidemiological and laboratory characteristics, defi-
nition of alcoholic liver disease as defined by the authors of the
individual studies considered for inclusion, technical failures in
undertaking liver biopsy and ultrasonography, cirrhosis estimated
by morphological score and ultrasonography, and information re-
lated to the QUADAS-2 items for evaluation of the risk of bias of
the studies (Whiting 2011).
In order to provide data for our analyses, the studies have to pro-
vide data that could help us calculate the true positive, false pos-
itive, true negative, and false negative diagnostic values of ultra-
sonography for diagnosing cirrhosis.
If information on any of the true positive, false positive, true nega-
tive, and false negative diagnostic test values or results are missing,
we will attempt to contact the authors of the included studies in
order to obtain missing information. We will also contact authors
if other types of information needed for this review are missing,
especially when the publication is in the form of an abstract or
poster presentation.
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We will use Excel and Review Manager 5 to add data required for
statistical analyses (RevMan 2012).
Assessment of methodological quality
Design flaws in test accuracy studies can produce biased results
(Lijmer 1999; Whiting 2004; Rutjes 2006). In addition, evalua-
tion of study results is quite often impossible due to incomplete
reporting (Smidt 2005).
To limit the influence of different biases, four review authors (CP,
GC, MP, and DN), in pairs or independently of one another, will
assess the bias risk of the included diagnostic test accuracy studies,
usingQUADAS-2 domains (Whiting 2011). A fifth review author
(ET) will act as an arbitrator in case of disagreements between the
authors assessing the bias risk of the studies. We will contact study
authors if information onmethodology is lacking in order to assess
correctly the risk of bias of the studies.
Appendix 2 shows the adopted items that will serve the purposes
of our review in addressing the participant spectrum, index test,
target condition, reference standard, and flow and timing, and
which answerswould also reflect the general quality of the included
studies.
We will classify studies at low risk of bias if all answers to the sig-
nalling questions of the four domains and applicability are pos-
itive, and, if the answers to the signalling questions of the four
domains and applicability are either negative or unclear (or a com-
bination of these), we will classify the studies at high risk of bias
(Jüni 1999; Whiting 2005).
We will use tabular and graphical displays to summarise
QUADAS-2 assessments.
Statistical analysis and data synthesis
We will carry out the analyses following Chapter 10 (Analysing
and Presenting Results) of the Cochrane Handbook for Systematic
Reviews of Diagnostic Test Accuracy (Macaskill 2010). We will use
the Review Manager 5 software for analyses and plots (RevMan
2012).
When we have assembled the majority of our studies, we will map
the individual index tests or index test indices in the individual
studies and on the basis thereof determine which to select formeta-
analyses. We will build two-by-two tables of ultrasonography per-
formance (true positive, true negative, false positive, false negative)
for each primary study and for each index test (ultrasonography
mode) and for the predefined target condition (cirrhosis). We will
estimate sensitivity, specificity, positive and negative likelihood ra-
tios (LR+ and LR-), positive and negative predictive values (PPV
and NPV) with their 95% confidence intervals (CI). First, we will
perform a graphical descriptive analysis of the included studies: we
will report forest plots (sensitivity and specificity separately, with
their 95% CIs) and we will provide a graphical presentation of the
studies in the receiver operating characteristic (ROC) space (sen-
sitivity plotted against 1 - specificity). Second, if appropriate, we
will perform a meta-analysis. If all studies provide dichotomised
data using a common cut-off, we will use the bivariate model and
we will provide the estimate of the summary operating point (the
point with mean sensitivity and mean specificity). Otherwise, we
will use the hierarchical summary ROC (HSROC) model and we
will provide a summary ROC curve (Macaskill 2010). We will
perform all analyses for each test separately.
In case of undetermined ultrasonography results, we will attempt
to follow the intention-to-diagnose approach following which we
will add uninterpretable test results as false positive or false neg-
atives, depending on the liver biopsy result. In this way, we hope
to avoid potential overestimation of diagnostic test accuracy of
ultrasonography (Schuetz 2012).
We will use the pooled estimates obtained from the fitted models
to calculate summary estimates of likelihood ratios. We will assess
the probability of ultrasonography to rule in or to rule out hepatic
cirrhosis by considering the estimates of likelihood ratios. A high
LR+ (usually greater than 10) means that there is a large increase
in post-test probability, starting from pre-test probability. A low
LR- (usually lower than 0.1) means that there is a large decrease in
post-test probability, starting frompre-test probability (Schoenfeld
1999). Likelihood ratio estimates can be used in clinical practice
to calculate post-test probabilities for individual people, starting
from patient-specific pre-test probabilities.
We will perform direct and indirect comparisons between the in-
dex tests by adding co-variates to the bi-variate or HSROCmodel
(Macaskill 2010). In case of inconsistency of the results obtained
through direct and indirect comparisons, we will report both re-
sults; otherwise, we will report one of the results, depending on
the availability of comparisons.
One review author (GC) will perform all statistical analyses using
SAS statistical software (SAS Institute Inc., Cary, NC, USA).
Investigations of heterogeneity
We do not expect that the ultrasonographic tests and indices used
for diagnosis of cirrhosis in people with alcoholic liver disease
would cause additional heterogeneity to those already mentioned
in Secondary objectives.
Whenever possible, we will evaluate the effect of the pre-specified
sources of heterogeneity on the accuracy estimates by adding some
relevant co-variates to the bivariate model (Secondary objectives).
Sensitivity analyses
If possible, depending on number of studies with low risk of bias,
we will assess the effect of risk of bias of the included studies on the
diagnostic accuracy by performing a sensitivity analysis, excluding
studies with high or unclear risk of bias, and perform a separate
sensitivity analysis excluding unblinded studies.
We will classify a study with high risk of bias if judged as high
risk of bias or unclear risk of bias in at least one of the domains of
QUADAS-2 (Appendix 2).
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We will also attempt to perform a sensitivity analysis of studies
with data received from study authors.
However, we may not identify a sufficient number of studies for
the planned sensitivity analyses.
Assessment of reporting bias
Wewill perform a funnel plot to investigate reporting bias visually,
using the statistical method suggested by Deeks et al. (Deeks
2005).
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A D D I T I O N A L T A B L E S
Table 1. Semi-quantitative histopathological scoring systems for progression of fibrosis to cirrhosis. Conversion grid for the
stages of hepatic fibrosis*
Stage of fibrosis
METAVIR Knodell Ishak Kleiner Desmet Brunt Batts-Ludvig
F0 F0 F0 F0 F0 F0 F0
F1 F1 F1 F1 F1 F1 F1
F1 F1 F2 F1 F1 F1 F1
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Table 1. Semi-quantitative histopathological scoring systems for progression of fibrosis to cirrhosis. Conversion grid for the
stages of hepatic fibrosis* (Continued)
F2 F3 F3 F2 F2 F2 F2
F3 F3 F4 F2 F3 F3 F3
F4 F4 F5 F3 F4 F4 F4
F4 F4 F6 F4 F4 F4 F4
METAVIR, Knodell, Ishak, Kleiner, Desmet, and Brunt scoring systems are used to classify fibrosis (and steatosis) due to alcoholic liver
disease. For references, please see review text.
*Adapted from Goodman 2007.
F = stage of hepatic fibrosis. F0: no fibrosis; F1: portal fibrous expansion; F2: thin fibrous septa emanating from portal triads; F3:
fibrous septa bridging portal triads and central veins; F4: cirrhosis. Clinically significant fibrosis is generally defined as F2 or greater on
the METAVIR scale from F0 to F4 with F4 being cirrhosis.
Clinically significant fibrosis is defined as Ishak fibrosis stage F3 to F6, and cirrhosis defined as Ishak fibrosis F5 or F6.
A P P E N D I C E S
Appendix 1. Search strategy
Database Time span Search strategy
Cochrane Hepato-Biliary Group Con-
trolled Trials Register
The issue of The Cochrane Library will be
given at review stage.
(ultrason* or ultrasound* or echograph* or
echotomograph* or doppler* or B-mode
or B-scan or grey*scale) AND ((hepatic or
liver) and (fibrosis or cirrhosis))
Cochrane Hepato-Biliary Group Diagnos-
tic Test Accuracy Register
Date will be given at review stage. (ultrason* or ultrasound* or echograph* or
echotomograph* or doppler* or B-mode
or B-scan or grey*scale) AND ((hepatic or
liver) and (fibrosis or cirrhosis))
The Cochrane Library Date will be given at review stage. #1 MeSH descriptor: [Ultrasonography]
explode all trees
#2 (ultrason* or ultrasound* or echograph*
or echotomograph* or doppler* or B-mode
or B-scan or grey*scale)
#3 #1 or #2
#4 MeSH descriptor: [Liver Cirrhosis] this
term only
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(Continued)
#5 ((hepatic or liver) and (fibrosis or cir-
rhosis))
#6 #4 or #5
#7 #3 and #6
MEDLINE (Ovid SP) 1946 to the date of search. 1. exp Ultrasonography/
2. (ultrason* or ultrasound* or echograph*
or echotomograph* or doppler* or B-
mode or B-scan or grey*scale).mp. [mp=
title, abstract, original title, name of sub-
stance word, subject heading word, key-
word heading word, protocol supplemen-
tary concept word, rare disease supplemen-
tary concept word, unique identifier]
3. 1 or 2
4. exp Liver Cirrhosis/
5. ((hepatic or liver) and (fibrosis or cir-
rhosis)).mp. [mp=title, abstract, original ti-
tle, name of substance word, subject head-
ing word, keyword heading word, protocol
supplementary concept word, rare disease
supplementary concept word, unique iden-
tifier]
6. 4 or 5
7. 3 and 6
EMBASE (Ovid SP) 1974 to the date of search. 1. exp echography/
2. (ultrason* or ultrasound* or echograph*
or echotomograph* or doppler* or B-mode
or B-scan or grey*scale).mp. [mp=title,
abstract, subject headings, heading word,
drug trade name, original title, device man-
ufacturer, drug manufacturer, device trade
name, keyword]
3. 1 or 2
4. exp liver cirrhosis/
5. exp liver fibrosis/
6. ((hepatic or liver) and (fibrosis or cirrho-
sis)).mp. [mp=title, abstract, subject head-
ings, heading word, drug trade name, orig-
inal title, device manufacturer, drug man-
ufacturer, device trade name, keyword]
7. 4 or 5 or 6
8. 3 and 7
Science Citation Index Expanded 1900 to the date of search. #3 4,352 #2 AND #1
#2 76,895 TS=((hepatic or liver) and (fi-
brosis or cirrhosis))
#1 425,695 TS=(ultrason* or ultra-
sound* or echograph* or echotomograph*
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(Continued)
or doppler* or B-mode or B-scan or
grey*scale)
Appendix 2. QUADAS-2
Domain Participant selection Index test Reference standard Flow and timing
Description Describe methods of
participant selection:
describe included par-
ticipants (prior testing,
presentation, intended
use of index test, and
setting):
The studies that ful-
fil the inclusion crite-
ria of this review should
have included partici-
pants of any sex and eth-
nic origin, over 16 years
old, and diagnosed with
alcoholic liver disease.
The participants could
have been hospitalised or
managed as outpatients.
The diagnosis of alco-
holic liver disease in the
study participants had to
be established based on
registered history of al-
cohol excessive intake of
sufficient duration and
quantity together with
clinical evidence of liver
disease expressed with
physical signs at exami-
nation and followed by
laboratory evidence of
liver disease. We will ex-
clude other causes of
liver disease such as vi-
ral hepatitis, autoimmu-
nity, metabolic diseases,
and toxins. To ascertain
Describe the index test
and how it was con-
ducted and interpreted:
Ultrasonography for di-
agnosing cirrhosis, con-
ducted either before or
after liver biopsy
Describe the reference
standard and how it
was conducted and in-
terpreted:
Liver biopsy with ≥ 6
portal tracts or length
of liver biopsy specimen
> 15 mm is considered
adequate in establishing
cirrhosis in people with
alcoholic liver disease
The morpho-
logical interpretation of
the liver biopsy samples
is reported with semi-
quantitative scores such
as METAVIR, Knodell,
Ishak, Kleiner, Scheuer,
or Brunt (see Table 1).
Describe any people
who did not receive the
index test(s) or refer-
ence standard (or both)
or who were excluded
from the 2 x 2 table
(refer to flow diagram)
: describe the time in-
terval and any inter-
ventions between in-
dex test(s) and refer-
ence standard:
As early cirrhosis may
reverse with time in
abstinent people, but
mild to moderate fibro-
sis may evolve to cirrho-
sis in non-abstinent peo-
ple, we will exclude par-
ticipants if the time in-
terval between diagnos-
tic liver biopsy and ul-
trasonography investiga-
tions is > 6 months
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(Continued)
the diagnosis of alcoholic
liver disease and study
the presence of cirrho-
sis, both ultrasonogra-
phy and liver biopsy have
to be performed, irre-
spective of the sequence
Signalling questions:
yes/no/unclear
Was a consecutive or
random sample of par-
ticipants enrolled?
Yes: all consecutive par-
ticipants or random sam-
ple of people with diag-
nosed alcoholic liver dis-
ease were enrolled in the
study
No: selected participants
were not included.
Unclear: insuffi-
cient data were reported
to permit a judgement
Were the index test re-
sults interpreted with-
out knowledge of the
results of the reference
standard?
Yes: ultrasonography test
results were interpreted
without knowledge of
the results of the liver
biopsy
No: ultrasonography re-
sults were interpreted
with knowledge of the
results of the liver biopsy
Unclear: insuffi-
cient data were reported
to permit a judgement
Is the reference stan-
dard likely to clas-
sify the target condi-
tion correctly?
Yes: if participants have
undergone liver biopsy
and the liver tissue spec-
imen was deemed ade-
quate for confident his-
tological assessment
No: the liver tissue speci-
men was not deemed ad-
equate for confident his-
tological assessment
Unclear: insuffi-
cient data were reported
to permit a judgement
Was there an appropri-
ate interval between in-
dex test(s) and refer-
ence standard?
Yes: the interval between
the ultrasonography and
liver biopsy was ≤ 6
months
No: the interval between
the ultrasonography test
and liver biopsy was >6
months
Unclear: insuffi-
cient data were reported
to permit a judgement
Was a patient-control
design avoided?
Yes: patient-control de-
sign was avoided.
No: patient-control de-
sign was not avoided.
Unclear: insufficient in-
formation was reported
to permit a judgement
If a threshold was used,
was it pre-specified?
Yes.
No.
Unclear: it is not re-
ported or not clearly de-
scribed.
Were the reference
standard results inter-
preted without knowl-
edge of the results of
the index test?
Yes: liver biopsy results
were interpreted without
knowledge of the results
of the ultrasonography
test
No: liver biopsy results
were interpretedwith the
knowledge of the results
of the ultrasonography
test
Unclear: insuffi-
cient data were reported
to permit a judgement
Did all participants re-
ceive the reference stan-
dard?
Yes: all participants un-
derwent the reference
standard, liver biopsy
No: not all participants
underwent liver biopsy.
Unclear: insuffi-
cient data were reported
to permit a judgement
Did the study avoid in-
appropriate
exclusions?
Yes: the study avoided
inappropriate exclusions
Did all participants re-
ceive the same reference
standard?
Yes: all participants re-
ceived the same refer-
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(e.g., difficult to diag-
nose participants, failure
at liver biopsy, failure on
ultrasonography)
No: the study excluded
participants inappropri-
ately.
Unclear: insuffi-
cient data were reported
to permit a judgement
ence standard, i.e., liver
biopsy
No: not all participants
received the same refer-
ence standard, i.e., liver
biopsy
Unclear: insuffi-
cient data were reported
to permit a judgement
Were all participants
included in the analy-
sis?
Yes:
all participants meeting
the selection criteria (se-
lected participants) were
included in the analysis,
or data on all the se-
lected participants were
available so that a 2 x
2 table including all se-
lected participants could
be constructed
No: not all participants
meeting the selection cri-
teriawere included in the
analysis or the 2 x 2 table
could not be constructed
using data on all selected
participants
Unclear: insuffi-
cient data were reported
to permit a judgement
Risk of bias: high/low/
unclear
Could the selection of
participants have intro-
duced bias?
High risk of bias: yes, if
the selection of partic-
ipants have introduced
bias
Low risk of bias: no, if
the selection of partic-
ipants have not intro-
duced bias
Unclear risk of bias: in-
sufficient data on partic-
ipants selection were re-
ported to permit a judge-
Could the conduct or
interpretation of the
index test have intro-
duced bias?
High risk of bias: if the
answer to the signalling
questions on the conduct
or interpretation of the
index test is ’no’
Low risk of bias: if the
answer to the signalling
questions on the conduct
or interpretation of the
index test is ’yes’
Unclear risk of bias: if
Could
the reference standard,
its conduct, or its in-
terpretation have intro-
duced bias?
High risk of bias: if the
answer to the signalling
questions on the refer-
ence standard, its con-
duct, or its interpreta-
tion is ’no’
Low risk of bias: if the
answer to the signalling
questions on the refer-
Could the participant
flow have introduced
bias?
High risk of bias: if the
answer to the signalling
questions on flow and
timing is ’no’
Low risk of bias: if the
answer to the signalling
questions on flow and
timing is ’yes’
Unclear risk of bias: if
the answers to the 4
signalling questions on
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ment on the risk of bias the answers to the 2
signalling questions on
the conduct or interpre-
tation of the index test
is either ’unclear’ or any
combination of ’unclear’
with ’yes’ or ’no’
ence standard, its con-
duct, or its interpreta-
tion is ’yes’
Unclear risk of bias: if
the answers to the three
signalling questions on
the reference standard,
its conduct, or its inter-
pretation is either ’un-
clear’ or any combina-
tion of ’unclear’ with
’yes’ or ’no’
flow and timing is either
’unclear’ or any combi-
nation of ’unclear’ with
’yes’ or ’no’
Concerns regard-
ing applicability: high/
low/unclear
Are there concerns that
the included partici-
pants do not match the
review question?
High concern: there is
high concern that the
included participants do
not match the review
question
Low concern: there is
low concern that the in-
cluded participants do
not match the review
question
Unclear concern: if it is
unclear.
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
High concern: there is
high concern that the
conduct or interpreta-
tion of the ultrasonogra-
phy test differs from the
way it is likely to be used
in clinical practice
Low concern: there is
low concern that the
conduct or interpreta-
tion of the ultrasonogra-
phy test differs from the
way it is likely to be used
in clinical practice
Unclear concern: if it is
unclear.
Are there concerns that
the target condition as
defined by the refer-
ence standard does not
match the review ques-
tion?
High concern: all partic-
ipants did not undergo
liver biopsy for cirrhosis
Low concern: all partic-
ipants underwent liver
biopsy for cirrhosis
If it is unclear.
--
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